Navigation Links
Analysis of Data Across Multiple Drug Eluting Stent Trials Reinforces Positive Clinical Performance of XIENCE V®

NEW ORLEANS, April 3, 2011 /PRNewswire/ -- A pooled analysis of the SPIRIT II, III, IV and COMPARE trials presented today further reinforces the positive clinical performance of Abbott's (NYSE: ABT) market-leading XIENCE V® Everolimus Eluting Coronary Stent System. As part of the analysis of all four trials, two-year results on the safety and efficacy of XIENCE V compared to TAXUS® Liberte® and TAXUS® Express2™ Paclitaxel-Eluting Coronary Stent Systems (TAXUS) were presented at the American College of Cardiology's (ACC) 60th Annual Scientific Session and i2 Summit 2011 in New Orleans.

In a presentation given by Dean J. Kereiakes, M.D., medical director of The Christ Hospital Heart and Vascular Center in Cincinnati, Ohio, predictors of artery re-blockage, cardiac death or heart attack were evaluated out to two years in nearly 7,000 patients from the SPIRIT II, III, IV and COMPARE clinical trials. The data demonstrated that use of XIENCE V resulted in significantly lower clinical event rates following a stent procedure. In the pooled analysis, XIENCE V demonstrated a 36 percent reduction in the risk of major adverse cardiac events (MACE) compared to TAXUS (7.3 percent for XIENCE V versus 11.1 percent for TAXUS, p-value<0.001). MACE is an important composite clinical measure of safety and efficacy outcomes for patients, defined as cardiac death, heart attack (myocardial infarction or MI), or retreatment of a lesion (ischemia-driven target lesion revascularization, or ID-TLR).

"XIENCE V consistently demonstrated low adverse cardiac event rates in trial after trial," said Dr. Kereiakes. "The SPIRIT II, III, IV, and COMPARE pooled analysis suggests that XIENCE V reduced the occurrence of adverse events compared to patients treated with the TAXUS stent. The low event rates demonstrated by XIENCE V in these trials are especially impressive given the complexity of patients in the SPIRIT IV and COMPARE trials and confirm that the results seen with XIENCE V in earlier randomized clinical trials are consistent with clinical practice."

XIENCE V Shows Positive Results in Data Presented at ACC

In addition to the 36 percent reduction in the risk of overall MACE compared to TAXUS, data also were presented at ACC from the pooled analysis that demonstrated the following for XIENCE V:

  • A 47 percent reduction in the risk of heart attack (2.9 percent for XIENCE V versus 5.5 percent for TAXUS, p-value<0.001)
  • A 40 percent reduction in the risk of cardiac death or heart attack (4.0 percent for XIENCE V versus 6.6 percent for TAXUS, p-value<0.001)  
  • A 36 percent reduction in the risk of ID-TLR (4.1 percent for XIENCE versus 6.6 percent for TAXUS, p-value<0.001)
  • A 70 percent reduction in the risk of stent thrombosis, defined as definite or probable according to ARC (Academic Research Consortium) (0.7 percent for XIENCE V vs. 2.3 percent for TAXUS, p-value<0.0001)

"The pooled analysis of the SPIRIT II, III, IV and COMPARE trials further supports the strong body of clinical evidence that has made XIENCE V a leading drug eluting stent technology for patients and physicians," said Charles A. Simonton, M.D., FACC, FSCAI, divisional vice president, Medical Affairs, and chief medical officer, Abbott Vascular. "XIENCE V's long-term clinical performance is backed by clinical data from more than 30,000 patients worldwide."  

The SPIRIT trials were sponsored and conducted by Abbott. SPIRIT IV included 3,690 patients, many of whom presented with multiple medical complexities, including more than 1,100 patients with diabetes, and patients with small vessels, long lesions, and multiple lesions. The COMPARE study was a physician-initiated trial involving 1,800 patients with complex vascular disease. This pooled analysis was performed independently of Abbott. TAXUS Liberte was the control in COMPARE and TAXUS Express2 was the control in SPIRIT II, SPIRIT III and SPIRIT IV.


Abbott's market-leading XIENCE V drug eluting stent is marketed in the United States, Europe, Japan and other international markets.

Everolimus, developed by Novartis Pharma AG, is a proliferation signal inhibitor, or mTOR inhibitor, licensed to Abbott by Novartis for use on its drug eluting vascular devices. Everolimus has been shown to inhibit in-stent neointimal growth in the coronary vessels following stent implantation, due to its anti-proliferative properties.

XIENCE V is indicated for improving coronary luminal diameter in patients with symptomatic heart disease due to de novo native coronary artery lesions (lesions less than or equal to 28 mm) with reference vessel diameters of 2.5 mm to 4.25 mm. Additional information about XIENCE V, including important safety information, is available online at or

About Abbott Vascular

Abbott Vascular is a global leader in cardiac and vascular care with market-leading products and an industry-leading pipeline. Abbott Vascular offers a comprehensive cardiac and vascular devices portfolio, including products for coronary artery disease, vessel closure, endovascular disease, and structural heart disease.

About Abbott

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs nearly 90,000 people and markets its products in more than 130 countries.

Abbott's news releases and other information are available on the company's Web site at

Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Advanced Cell Diagnostics and Definiens Partner to Develop Tool for Quantitative Biomarker Analysis
2. "The State of the Medical Marijuana Markets 2011" First Ever Investor-Grade Analysis Report of the Marijuana Marketplace in the United States
3. Reportlinker Adds Triple Analysis: Colorectal Cancer, Leukemia and Pancreatic Cancer
4. Reportlinker Adds Triple Analysis: Colorectal Cancer, Lung Cancer and Lymphoma
5. Applied Science Laboratories Releases Revolutionary Eye Tracking Analysis Software
6. RainDance Technologies and Ambry Genetics Expand Collaboration to Address ADME Analysis
7. InstaCare Announces Receipt of Technology and Patent Value Analysis Penned by Joseph Wolf, Ph.D and William Walling, CFA
8. Analysis of Calipers Phase I EPA ToxCast™ Data Published in Leading Scientific Journal
9. Anthera Announces Conference Call to Discuss Analytical Method and Timing of Upcoming VISTA-16 Biomarker Analysis
10. Reportlinker Adds U.S. Pain Management Products & Services: a Market Analysis - 7th Edition
11. Reportlinker Adds Generic and innovative drug market in CE countries 2011 - Comparative analysis, reimbursement policies and development forecasts for 2011-2013
Post Your Comments:
(Date:6/24/2016)... Research and Markets has announced the ... Tests" report to their offering. ... The World Market for Companion Diagnostics covers the ... analysis in the report includes the following: ... Kits) by Region (N. America, EU, ROW), 2015-2020 , ...
(Date:6/24/2016)... June 24, 2016   Pulmatrix, Inc ., (NASDAQ: ... innovative inhaled drugs, announced today that it was added ... reconstituted its comprehensive set of U.S. and global ... is an important milestone for Pulmatrix," said Chief Executive ... awareness of our progress in developing drugs for crucial ...
(Date:6/24/2016)... KNOXVILLE, Tenn. , June 24, 2016 /PRNewswire/ ... market providing less invasive and more durable cerebrospinal ... million in funding.  The Series-A funding is led ... the Lighthouse Fund, and other private investors.  Arkis, ... less-invasive neurosurgical instrumentation and the market release of ...
Breaking Medicine Technology:
(Date:6/25/2016)... Washington, D.C. (PRWEB) , ... June 25, 2016 ... ... will discuss health policy issues and applications at AcademyHealth’s Annual Research Meeting June ... share their work on several important health care topics including advance care planning, ...
(Date:6/25/2016)... ... , ... First Choice Emergency Room , the largest network of independent ... Director of its new Mesquite-Samuell Farm facility. , “We are pleased to announce ... Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether ... latter, setting the bar too high can result in disappointment, perhaps even self-loathing. However, ... their goal. , Research from reveals that behind the tendency ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her ... would lash out at his family verbally and physically. , “When something upset him, he ... he would use it. He would throw rocks at my other children and say he ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Comfort Keepers® of ... Cancer Society and the Road To Recovery® program to drive cancer patients to and ... other adults to ensure the highest quality of life and ongoing independence. Getting ...
Breaking Medicine News(10 mins):